Nucelis specializes in the development of sustainable, low-carbon ingredients through its innovative Accelerated Strain Advancement Platform (ASAP™). This platform integrates a suite of precision gene-editing technologies, known as the Rapid Trait Development System (RTDS™), with advanced fermentation techniques and proprietary downstream processing methods. By leveraging these technologies, Nucelis aims to create high-value, non-transgenic specialty ingredients for various industries, including nutrition, personal care, and flavor and fragrance. The company has successfully demonstrated the versatility of ASAP in producing key nutritional products, such as ergosterol and vitamin D2, showcasing its commitment to addressing market needs efficiently and sustainably.

The company's approach to strain development involves utilizing its proprietary gene-editing technologies to make non-transgenic modifications in microorganisms, including yeast, bacteria, and algae. Nucelis has invested in state-of-the-art fermentation facilities in San Diego, equipped with both lab and pilot-scale bioreactors, allowing for the optimization of production conditions. This infrastructure supports a seamless transition from genetic optimization to the extraction and purification of final products, ensuring high-quality outcomes. By combining expertise in fermentation and downstream processing, Nucelis positions itself as a leader in delivering specialty ingredients that meet or exceed market standards for purity and performance.

United States

Nucelis is a provider of ingredient solutions for personal care, nutrition, and flavor and fragrance markets, emphasizing high-value, performance-focused, and sustainably-sourced products.

Nucelis

Company Details